Dana Campbell, PA
Surgical · London, KYNPI 1750698866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novartis at 25.0% of the total.
Across 60 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$285
- AbbVie$166
- Novo Nordisk$94
- Kestra Medical Technology Services, Inc.$89
- Sanofi-aventis U.S. LLC$78
- Amgen$76
- plus $353 from 9 others
What the payments were for
- Food & beverage$1,141100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $285 |
| AbbVie | 3 | $166 |
| Novo Nordisk | 4 | $94 |
| Kestra Medical Technology Services, Inc. | 3 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Amgen | 5 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $68 |
| Merck | 4 | $66 |
| Actelion Pharmaceuticals US, Inc. | 3 | $54 |
| Pfizer | 3 | $45 |
| AstraZeneca | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$1,141 in reported general payments places this provider in the 65th percentile of 72 surgical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $79,145 |
| Repatha SureclickEvolocumab | 33 | $27,482 |
| EntrestoSacubitril/Valsartan | 23 | $24,610 |
| XareltoRivaroxaban | 17 | $24,205 |
| BrilintaTicagrelor | 26 | $21,354 |
| JardianceEmpagliflozin | 19 | $18,309 |
| Ranolazine ErRanolazine | 79 | $10,229 |
| VascepaIcosapent Ethyl | 15 | $7,388 |
| NexletolBempedoic Acid | 12 | $7,333 |
| Metoprolol Succinate | 119 | $1,428 |
| Metoprolol Tartrate | 147 | $822 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $790 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 107 | $784 |
| Atorvastatin Calcium | 127 | $559 |
| Rosuvastatin Calcium | 69 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $79,14588 claims |
| NovartisEntresto | $285 | $24,61023 claims |
| Johnson & JohnsonXarelto | $17 | $24,20517 claims |
| AstraZenecaBrilinta | $39 | $21,35426 claims |
| Boehringer IngelheimJardiance | $12 | $18,30919 claims |
| Esperion Therapeutics, Inc.Nexletol | $20 | $7,33312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 72 surgical providers in Kentucky.
Other surgical in London
- Luke RobinsonLondon$1K
- William MeadorsLexington$16K
- Mark GrandonLouisville$9K
- Adam LocklarLexington$4K
- Jamie BlackLexington$4K
- David YeagerLouisville$4K
- Korey PlewinskiLouisville$4K
- Hannah JohnsonBardstown$4K
- Rachel WeaverLexington$3K
- Elizabeth KordikLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.